Abstract
The rapid increase of circulating, antibiotic-resistant pathogens is a major ongoing global health crisis, and arguably, the end of the “golden age of antibiotics” is looming. This has led to a surge in research and development of alternative antimicrobials, including bacteriophages, to treat such infections (phage therapy). Isolating natural phage variants for the treatment of individual patients is an arduous and time-consuming task. Furthermore, the use of natural phages is frequently hampered by natural limitations, such as moderate in vivo activity, the rapid emergence of resistance, insufficient host range, or the presence of undesirable genetic elements within the phage genome. Targeted genetic editing of wild-type phages (phage engineering) has successfully been employed in the past to mitigate some of these pitfalls and to increase the therapeutic efficacy of the underlying phage variants. Clearly, there is a large potential for the development of novel, marker-less genome-editing methodologies to facilitate the engineering of therapeutic phages. Steady advances in synthetic biology have facilitated the in vitro assembly of modified phage genomes, which can be activated (“rebooted”) upon transformation of a suitable host cell. However, this can prove challenging, especially in difficult-to-transform Gram-positive bacteria. In this chapter, we detail the production of cell wall-deficient L-form bacteria and their application to activate synthetic genomes of phages infecting Gram-positive host species.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Prestinaci F, Pezzotti P, Pantosti A (2015) Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health 109(7):309–318
De Oliveira DMP, Forde BM, Kidd TJ et al (2020) Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev 33(3):e00181-19
Nick JA, Dedrick RM, Gray AL et al (2022) Host and pathogen response to bacteriophage engineered against mycobacterium abscessus lung infection. Cell 185(11):1860–74 e12
Schooley RT, Biswas B, Gill JJ et al (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61(10)
Dedrick RM, Guerrero-Bustamante CA, Garlena RA et al (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 25(5):730–733
Pires DP, Costa AR, Pinto G et al (2020) Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev 44(6):684–700
Skurnik M, Pajunen M, Kiljunen S (2007) Biotechnological challenges of phage therapy. Biotechnol Lett 29(7):995–1003
Torres-Barcelo C (2018) Phage therapy faces evolutionary challenges. Viruses 10:6
Egido JE, Costa AR, Aparicio-Maldonado C et al (2022) Mechanisms and clinical importance of bacteriophage resistance. FEMS Microbiol Rev 46(1):fuab048
Meile S, Sarbach A, Du J et al (2020) Engineered reporter phages for rapid bioluminescence-based detection and differentiation of viable listeria cells. Appl Environ Microbiol 86(11):e00442
Funatsu T, Taniyama T, Tajima T et al (2002) Rapid and sensitive detection method of a bacterium by using a GFP reporter phage. Microbiol Immunol 46(6):365–369
Du J, Meile S, Baggenstos J et al (2023) Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors. Nat Commun 14(1):4337
Dunne M, Rupf B, Tala M et al (2019) Reprogramming bacteriophage host range through structure-guided design of chimeric receptor binding proteins. Cell Rep 29(5):1336–50 e4
Matsuda T, Freeman TA, Hilbert DW, et al., Stapleton PP et al (2005) Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137(6):639–646
Paul VD, Sundarrajan S, Rajagopalan SS et al (2011) Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol 11:195
Meile S, Du J, Dunne M, Kilcher S et al (2022) Engineering therapeutic phages for enhanced antibacterial efficacy. Curr Opin Virol 52:182–191
Ando H, Lemire S, Pires DP et al (2015) Engineering modular viral scaffolds for targeted bacterial population editing. Cell Syst 1(3):187–196
Jaschke PR, Lieberman EK, Rodriguez J et al (2012) A fully decompressed synthetic bacteriophage oX174 genome assembled and archived in yeast. Virology 434(2):278–284
Kilcher S, Studer P, Muessner C et al (2018) Cross-genus rebooting of custom-made, synthetic bacteriophage genomes in L-form bacteria. Proc Natl Acad Sci U S A 115(3):567–572
Shin J, Jardine P, Noireaux V (2012) Genome replication, synthesis, and assembly of the bacteriophage T7 in a single cell-free reaction. ACS Synth Biol 1(9):408–413
Garamella J, Marshall R, Rustad M et al (2016) The All E. coli TX-TL toolbox 2.0: a platform for cell-free synthetic biology. ACS Synth Biol 5(4):344–355
Rustad M, Eastlund A, Jardine P et al (2018) Cell-free TXTL synthesis of infectious bacteriophage T4 in a single test tube reaction. Synth Biol (Oxf) 3(1):ysy002
Emslander Q, Vogele K, Braun P et al (2022) Cell-free production of personalized therapeutic phages targeting multidrug-resistant bacteria. Cell Chem Biol 29(9):1434–45 e7
Kapteijn R, Shitut S, Ashmann D et al (2022) DNA uptake by cell wall-deficient bacteria reveals a putative ancient macromolecule uptake mechanism. bioRxiv
Woo PC, To AP, Lau SK et al (2003) Facilitation of horizontal transfer of antimicrobial resistance by transformation of antibiotic-induced cell-wall-deficient bacteria. Med Hypotheses 61(4):503–508
White TB, Doyle RJ, Streips UN (1981) Transformation of a Bacillus subtilis L-form with bacteriophage deoxyribonucleic acid. J Bacteriol 145(2):878–883
Studer P, Borisova M, Schneider A et al (2016) The absence of a mature cell wall sacculus in stable listeria monocytogenes L-form cells is independent of peptidoglycan synthesis. PLoS One 11(5):e0154925
Acknowledgments
We kindly thank Prof. Alex O’Neill (University of Leeds) for providing the SH1000ΔmutS strain used in this study.
Conflict of Interest Statement
S.K. is a part-time employee of Micreos Pharmaceuticals, and M.J.L. is a scientific advisor to Micreos Pharmaceuticals. J.F. and S.M. declare no conflict of interest.
Funding
S.K. and S.M. have been funded through an Ambizione grant (PZ00P3_174108) from the Swiss National Science Foundation (SNSF).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Fernbach, J., Meile, S., Kilcher, S., Loessner, M.J. (2024). Genetic Engineering and Rebooting of Bacteriophages in L-Form Bacteria. In: Azeredo, J., Sillankorva, S. (eds) Bacteriophage Therapy. Methods in Molecular Biology, vol 2734. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3523-0_16
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3523-0_16
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3522-3
Online ISBN: 978-1-0716-3523-0
eBook Packages: Springer Protocols